Contineum Therapeutics ($CTNM) Stock Hub: Can PIPE-791 Win in IPF With Cash Guided to Mid-2029?

Bull, base and bear scenarios

Bull case

Bristol Myers Squibb’s ALOFT-IPF Phase 3 confirms that LPA1 antagonism slows lung-function decline with a manageable liver profile, PROPEL-IPF keeps enrolling at the pace its site build-out suggests, and the PIPE-791 safety record stays clean through 2027. In that path Contineum reaches its 2028 readout with cash to spare, and a positive 26-week FVC result would give it a differentiated once-daily drug in a validated class, plus negotiating leverage for partnership or Phase 3 funding. Johnson & Johnson finding a use for PIPE-307 would be an extra, not a requirement.

Base case

PIPE-791 remains the central program and the company funds recruitment and follow-up from existing resources. The BMS data settle the class question only partially, leaving PIPE-791’s fate to its own trial. PIPE-307 contributes uncertain optionality pending J&J’s assessment, and the share price tracks sector sentiment and competitor news more than company events, because Contineum itself has few scheduled disclosures before 2028 beyond quarterly reports.

Bear case

The BMS Phase 3 disappoints on efficacy or reveals a liver signal the market reads as a class effect, PROPEL-IPF recruitment slows or the protocol has to add monitoring, and J&J ends PIPE-307 development. Spending rises toward the level implied by the runway guidance while sentiment deteriorates, and the company faces a choice between a smaller program and issuing equity below the December 2025 offering price of $12.25.

Conditional editorial scenarios, without assigned probabilities or price targets.

What Would Falsify This Reading

The reading above rests on a few testable claims: that the LPA1 class works and is safe enough, that PIPE-791 can show its own benefit in PROPEL-IPF, and that the company’s cash lasts to the readout. These observations would contradict it.

• A failed or unsafe ALOFT-IPF. If Bristol Myers Squibb’s Phase 3 shows no meaningful FVC benefit for admilparant, or a confirmed liver-safety signal, the case for the class and for PIPE-791 as a better member of it weakens before Contineum reports.
• A liver or blood-pressure signal in PIPE-791 trials. Any protocol change for safety monitoring, a clinical hold or a serious adverse-event pattern in PROPEL-IPF would undercut the main differentiation argument.
• A later primary completion. A registry estimate moved well beyond May 2028 would compress the cash cushion that management sets at roughly one year past the trial.
• A shorter runway or early ATM use. Guidance cut below mid-2029, or ATM sales well before data, would show that spending is outpacing the plan described on July 30, 2026.
• A positive J&J decision on PIPE-307. A new trial or a milestone payment would contradict the reading of PIPE-307 as residual optionality, in the favorable direction.

None of these is a prediction. They are the observations that would overturn the analysis that follows, listed so that readers can check them rather than take the reading on trust.

01 Business model and the current pipeline

Contineum Therapeutics, Inc. is a clinical-stage company in San Diego that discovers and develops oral small molecules. It was incorporated in Delaware in 2009 as Pipeline Therapeutics and adopted its current name in November 2023, before its April 2024 Nasdaq listing. It has no approved product, and its Form 10-Q for the quarter ended June 30, 2026 reports no revenue for the first half of the year.

The July 2026 corporate presentation filed with the SEC shows a short pipeline. PIPE-791, an LPA1 receptor antagonist, is in Phase 2 for idiopathic pulmonary fibrosis (IPF) and has completed an exploratory Phase 1b study in chronic pain. CTX-343, a peripherally restricted LPA1 antagonist, sits on the chart with a footnote: the company has decided to defer further clinical development until funding is obtained specifically for that program. PIPE-307, also called JNJ-5120, is a selective M1 receptor antagonist licensed worldwide to Janssen Pharmaceutica NV, a Johnson & Johnson company, which has sole discretion over further development. Undisclosed discovery programs complete the list.

The July 30 update narrowed discovery work to inflammatory and fibrotic diseases and announced a limited workforce reduction in research, including the departure of chief scientific officer Daniel Lorrain, a member of the founding executive team. The company now describes itself as pioneering therapies for “inflammatory and fibrotic diseases”, whereas releases through April 2026 used the broader “neuroscience, inflammation and immunology” label.

The scientific basis of PIPE-791 was published in the Journal of Medicinal Chemistry on June 29, 2026 (Chen et al.), describing a scaffold that gives slow, tight binding to LPA1, brain penetration and low once-daily oral dosing. A publication describes chemistry and preclinical pharmacology; it is not clinical evidence of benefit. The practical consequence of the July reorganization: value now depends overwhelmingly on PIPE-791 in IPF.

July 2026 corporate presentation (SEC) · Q2 2026 release (SEC) · J. Med. Chem. publication release

02 September result: MOONLIGHT-1 and the PIPE-307 reset

On September 14, 2026 Contineum announced that the Phase 2 MOONLIGHT-1 study of JNJ-5120/PIPE-307 in major depressive disorder did not meet its primary efficacy endpoint, the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 5 compared with placebo. The drug was well tolerated with no new safety signals. Johnson & Johnson continues to evaluate the data, including prespecified exploratory endpoints, to assess the totality and clinical relevance of the findings before deciding on next steps. The release is filed as Exhibit 99.1 to an 8-K, so the wording can be checked against the filing itself.

The ClinicalTrials.gov record, updated by Janssen on September 25, 2026, adds detail. The study is now listed as completed, with actual primary completion on June 25, 2026 and study completion on August 10, 2026. It enrolled 105 participants according to the registry, while Contineum’s July 30 release and Form 10-Q referred to 107 adults enrolled in June; the gap may reflect randomized versus enrolled counts and is not explained in the sources reviewed. The design used three arms across two double-blind periods: dose A throughout, dose A followed by dose B, and placebo, at 44 listed sites. A five-day primary endpoint was an ambitious test of a rapid-onset hypothesis.

The result follows the November 20, 2025 VISTA readout in relapsing-remitting multiple sclerosis, where PIPE-307 failed its prespecified primary and secondary efficacy endpoints, including binocular 2.5% low-contrast letter acuity at week 26, in a study the registry lists with 182 patients. Two misses in two indications make a third attempt less likely, though J&J has not announced a decision. Nothing in the September filing terminates or restarts the program.

The financial link is indirect. Contineum’s PIPE-307 spending had already fallen to a credit of $0.3 million in Q2 2026 after VISTA ended, so the miss does not change the cost base. What it removes is the near-term possibility of milestone payments from the roughly $1.0 billion milestone pool and of a partner-funded Phase 3.

September 14 release, SEC Exhibit 99.1 · MOONLIGHT-1 registry · VISTA release, November 20, 2025 · VISTA registry

03 PIPE-791 and PROPEL-IPF: the controlled efficacy test

PROPEL-IPF is the event that decides the company. It enrolls adults aged 40 or older with an IPF diagnosis made within seven years under the 2022 international guideline, a centrally read high-resolution CT consistent with usual interstitial pneumonia, and a percent-predicted FVC of at least 40%. Patients with other interstitial lung diseases, pulmonary hypertension requiring multiple drugs, a recent exacerbation, severe kidney impairment or moderate-to-severe liver impairment are excluded. Background nintedanib or pirfenidone is allowed, so PIPE-791 must show an effect on top of drugs that already slow decline.

The 26-week primary endpoint mirrors the Phase 2 design that BMS used for its second-generation LPA1 antagonist, which reported slower FVC decline at 26 weeks. The choice keeps the trial short; it also means the result will speak to lung-function slope, not survival or hospitalization.

The site footprint has grown quickly. On July 30 the company cited more than 55 sites online in eight countries; on October 2 the registry listed 89 recruiting locations across Argentina (15), Israel (11), South Korea (9), Australia (8), Canada (7), the United Kingdom (7), Chile (5), New Zealand, Peru, Poland, Serbia and Taiwan (4 each), Greece (3), Spain (2), France and Portugal (1 each). No U.S. location appears on the record. Site listings are a sponsor-maintained operational clue, not an enrollment total, and the company has not disclosed how many patients are randomized.

Estimated primary completion is the expected date of the last primary-endpoint measurement, not a commitment to publish topline data on a given day. Because management sets the runway at about one year past trial completion, any slip matters twice: for the catalyst and for the cash cushion.

PROPEL-IPF registry, updated October 2, 2026 · July 30, 2026 company update (SEC) · July 2026 presentation, trial schema

04 What earlier PIPE-791 data show: occupancy, safety and the pain signal

Three earlier studies form the clinical base for PIPE-791. In healthy volunteers, single doses from 1 to 20 mg and multiple doses up to 10 mg for 14 days produced no dose-limiting adverse events, no notable laboratory changes and no findings in vital signs, ECG or telemetry, according to the company’s presentation. The Phase 1b PET study reported on September 18, 2025, with 12 healthy volunteers and four patients with progressive multiple sclerosis, showed high brain receptor occupancy with plasma EC50 values of 37 ng/mL at 24 hours and 12 ng/mL at 168 hours, and the company said planned Phase 2 doses would exceed 90% target coverage at trough with once-daily dosing. Lung occupancy could not be measured directly; the company relies on preclinical brain-lung correlation.

The exploratory chronic-pain trial, reported on April 30, 2026, enrolled 43 patients, 23 with chronic osteoarthritis pain (COAP) and 20 with chronic low back pain (CLBP), in a four-week crossover with 10 mg once daily. It met its primary objective of safety and tolerability: most adverse events were mild to moderate, there were no serious adverse events, the most common were headache (three patients) and fatigue (two), and blood pressure and orthostatic measures showed no clinically meaningful changes.

The pain numbers are small and must be read as exploratory. In osteoarthritis pain, PIPE-791 reduced weekly average pain more than placebo in both periods, with overlapping confidence intervals. In low back pain the first period favored the drug, but in the second period patients on PIPE-791 showed no improvement while those on placebo did; the crossover had no washout between periods, which can blur carry-over effects. The company itself emphasized the COAP data and said it is “contemplating next steps”; no pain trial has been announced since.

The company’s owned evidence so far is pharmacology, safety and a numerical pain signal, not a controlled efficacy result in its lead indication.

PET trial release, September 18, 2025 (SEC) · Pain trial release, April 30, 2026 (SEC) · Pain trial registry · Phase 1 safety summary

05 The LPA1 class: Bristol Myers Squibb, ALOFT and the liver question

Contineum does not compete in an empty field. Bristol Myers Squibb is two Phase 3 programs ahead with admilparant, and Contineum’s own July 2026 presentation lists the ALOFT-IPF completion, expected in the fourth quarter of 2026, among “significant developments and potential derisking” for the class. The registry estimate for the IPF trial’s primary completion is October 6, 2026. BMS controls when results are announced.

The class history is double-edged, and Contineum’s slides spell it out. BMS’s first LPA1 antagonist, BMS-986020, showed dose-dependent slowing of FVC decline at 26 weeks in a 143-patient Phase 2, but severe off-target hepatobiliary toxicity led to early termination. The second-generation BMS-986278 removed that liability and slowed FVC decline at 26 weeks at 60 mg twice daily in IPF and in progressive pulmonary fibrosis. Contineum argues PIPE-791 improves on admilparant with once-daily dosing, no titration, no hypotension observed and brain penetration.

On September 30, 2026 the trade press reported, with confirmation from a BMS spokesperson, a BMS amendment to the long-term extension of the ALOFT program that classifies liver injury as an important potential risk and adds closer monitoring, after a limited number of liver events and the death of a participant from multi-organ failure; the spokesperson said it was unclear whether that participant received admilparant and that independent monitors had repeatedly recommended the study continue. BMS has not issued a press release or regulatory filing on the amendment; the details come from the trade press (BioPharma Dive, September 30, BioSpace, October 1).

The read-through works in both directions. A clean, effective ALOFT-IPF result would validate the target in the largest trial yet run in the class and probably raise interest in follow-on molecules; a liver signal or a weak effect would raise the bar for PIPE-791 before its own data exist. The standard of care is also moving: in October 2025 the FDA approved Boehringer Ingelheim’s Jascayd (nerandomilast) for IPF, the first new IPF drug in more than a decade, so any new entrant must eventually show value alongside three approved therapies.

ALOFT-IPF registry · ALOFT-PPF registry · Contineum July 2026 presentation, class slides · Boehringer Ingelheim: Jascayd FDA approval

06 Catalyst timeline and decision ownership

The calendar shows the main difficulty for a Contineum holder: between now and 2028 the company controls very few scheduled events. Most sentiment-moving events are decided by others: BMS for the class readout, J&J for PIPE-307.

No FDA target action date exists for any Contineum program, because none is close to a marketing application. Trial completion, topline announcement, a Phase 3 decision, a regulatory filing and an approval are distinct events, years apart in a normal IPF development path. The company was scheduled for a fireside chat at the Morgan Stanley Global Healthcare Conference on September 15, 2026, the day after the MOONLIGHT-1 release; no transcript was reviewed for this analysis.

Morgan Stanley conference notice, August 25, 2026 · ALOFT-IPF registry · PROPEL-IPF registry

07 Cash, operating costs and runway

The balance sheet is the strongest part of the story. Liquid resources fell by $26.3 million in the first half of 2026, which is close to the $27.8 million of operating cash used, partly offset by $1.3 million from option exercises and the employee stock purchase plan. The cash-only line fell from $75.6 million to $14.7 million because money moved into securities.

The arithmetic behind the runway is worth doing, because it reveals the plan. Spreading $236.6 million evenly over the 36 months from July 2026 to mid-2029 gives about $6.6 million a month, or roughly $79 million a year (a Merlintrader calculation, not company guidance). The first-half 2026 operating cash use ran at about $4.6 million a month. Management’s guidance therefore assumes spending rises well above the current rate, as PROPEL-IPF enrolls fully and the company prepares what follows, or it keeps a reserve. Either way, the current burn alone would not exhaust cash by mid-2029.

Interest income is a real contributor: $4.8 million in six months offset about 14% of operating expenses. Falling short-term rates would shrink that cushion. Stock-based compensation of $7.7 million in the half was non-cash.

The runway is a management estimate tied to the current operating plan. The sources reviewed do not describe it as covering a Phase 3 program for PIPE-791, a new pain trial or co-funding of a PIPE-307 Phase 3, and the 10-Q’s formal liquidity statement covers “at least the next 12 months”. A long runway buys a scientific answer; it does not pay for commercialization.

SEC Form 10-Q, quarter ended June 30, 2026 · Management runway statement

08 Spending by program and what the cost mix means

The segment table in the 10-Q shows where the money goes, and it confirms the strategic shift in numbers. Direct external spending on PIPE-791 rose to $13.2 million in the first half of 2026 from $11.7 million a year earlier, while PIPE-307 spending vanished once the VISTA study closed and CTX-343 shrank to $0.6 million. In the second quarter, PIPE-791 absorbed 56% of total R&D, and the company attributed a $1.4 million increase in contract-research costs specifically to the IPF Phase 2.

Total R&D actually fell 10% year on year in the second quarter, to $12.7 million, because the completed VISTA, PET and pain studies stopped generating costs faster than PROPEL-IPF ramped up. That decline is temporary by construction: a 324-patient, 26-week global trial at nearly 90 sites costs more each quarter as enrollment advances. The runway arithmetic in the previous section already implies a higher spending rate.

General and administrative expense rose 23% to $4.7 million in the quarter, driven by $0.7 million more stock-based compensation and higher personnel costs. Stock-based compensation within R&D also rose, to $1.8 million in the quarter from $1.1 million. These are non-cash costs, but they are not free for shareholders: they arrive as new shares.

These are accounting expenses, not cash flows; on the June numbers, resources are concentrated where the value lies.

SEC Form 10-Q: segment and R&D tables

09 Shares, ATM capacity and dilution

The economic share count is 37.62 million: 32.96 million voting Class A shares and 4.66 million non-voting Class B shares, which convert into Class A. In the first quarter of 2026, 1,420,838 Class B shares converted. A conversion moves a share from one class to the other; it does not create a new economic share. Providers often quote only the Class A count, around 32.95 million.

Dilution has been the main funding tool. Through June 30, 2026 Contineum raised about $431.6 million of gross proceeds from equity, plus the $50 million J&J upfront. In 2025 it sold 3,241,110 shares through its first at-the-market program for net proceeds of $19.0 million, an average of about $5.86 per share net (calculated). In December 2025, after the VISTA failure, it sold 8,097,570 shares in a public offering at $12.25, for net proceeds of $93.0 million. In March 2026 it renewed the ATM with Leerink Partners for up to $100 million more, and it sold nothing under the amended program in the first half.

The equity overhang is larger than the ATM alone. Options on 7.66 million shares equal about 20% of the economic share count, with a weighted-average exercise price of $10.99, below the October 1 reference price. Together with the unused plan reserves, the 10-Q lists 15.45 million shares reserved for future issuance, a figure that includes the 4.66 million Class B shares already counted in the total.

An ATM is an option, not an obligation, and management has not used it since the December raise. The risk is a different one: if PROPEL-IPF succeeds, a Phase 3 program will cost far more than the remaining cash, and the company will need a partner, new equity or both.

SEC Form 10-Q: cover, equity notes and liquidity

10 Johnson & Johnson agreement, governance and management

The February 2023 license gave Janssen Pharmaceutica NV exclusive worldwide rights to PIPE-307 in all indications. Contineum received a $50.0 million upfront payment and, according to its July 2026 presentation, a $25 million equity investment. It is eligible for approximately $1.0 billion in milestones and tiered royalties from the low double digits to the high teens on net sales. If J&J starts a first Phase 3 trial, Contineum may opt to co-fund a portion of Phase 3 and later development costs, capped annually, in exchange for royalties one to two percentage points higher.

Three clauses matter more after September 14. J&J decides alone whether to develop PIPE-307 further, in depression, multiple sclerosis or any other indication. The agreement restricts what Contineum may disclose about the program, so investors may learn of a decision late or in limited form. And the 10-Q states that all variable consideration remained fully constrained at June 30, 2026, with no revenue recognized in the first halves of 2025 and 2026: the milestone pool carries no value in the accounts.

Chief executive Carmine Stengone leads the company; Peter Slover is chief financial officer and signs its SEC filings; Timothy Watkins, M.D., is chief medical officer and head of development and fronted the April pain data. Daniel Lorrain, chief scientific officer since March 2018 and a member of the founding executive team, left in the July research reduction; his October 1 Form 144 still lists him as an officer, a filing description rather than a statement on his current role. At the June 26, 2026 annual meeting shareholders re-elected Class II directors Evert Schimmelpennink, Lori M. Lyons-Williams and Diego Miralles, M.D., through 2029, and ratified Ernst & Young as auditor.

Contineum is an emerging growth company with a dual-class structure in which Class B shares carry economic rights but no votes. The 10-Q reported that no director or officer adopted or terminated a 10b5-1 trading plan in the second quarter.

SEC Form 10-Q: license note · July 2026 presentation: deal terms · Annual meeting results, Form 8-K · Workforce and management update

11 Ownership, insiders, analysts and short interest

The three most recent Schedule 13G filings show hedge-fund and index-manager ownership typical of a well-funded small-cap biotech. Each measures holdings at June 30, 2026, before the September news; positions may have changed since. Millennium’s amendment reported a holding below the 5% reporting threshold.

Insider activity since July consists of small, pre-planned sales. Carmine Stengone exercised 2,500 options at $1.01 and sold 2,500 shares on August 3 (weighted average $16.0116) and again on September 8 (weighted average $16.4566), both under a 10b5-1 plan adopted on September 23, 2025, before either readout. Daniel Lorrain sold 9,520 shares on August 3 and on September 1 under a 10b5-1 arrangement, and his October 1 Form 144 gives notice of 4,170 more, with a stated aggregate market value of $55,961.40. The amounts are small and were scheduled in advance.

Provider fields use their own share basis and cutoffs and should not be added together. The aggregate target of $22.00 is a provider average of unnamed brokers, not a Merlintrader estimate and not a forecast; no single house target is reproduced here without a citable original note. The Russell 2000 flag is a provider field that was not checked against the FTSE Russell constituent file, so passive demand is not treated as a confirmed factor.

Balyasny 13G/A · BlackRock 13G · Millennium 13G/A · Form 4, August 3 · Form 4, September 8 · Form 144, October 1 · Finviz provider page

12 Valuation arithmetic: what the market already pays for

At the October 1 close, the market valued both share classes at about $489 million. Subtracting the June 30 liquid resources leaves roughly $252 million that investors attribute to the pipeline, mainly PIPE-791 in IPF, before deducting third-quarter spending, which at the first-half pace would be about $14 million. All of these figures are Merlintrader calculations from dated inputs, not a fair-value estimate.

Put differently, slightly less than half of the market value is backed by cash and securities and slightly more than half is a bet on the drug. That premium rests on the LPA1 class being real and safe, which explains sensitivity to competitor events.

The comparison with the December 2025 offering is instructive. Investors then paid $12.25 a share, after VISTA had failed and before PROPEL-IPF dosed its first patient. On October 1 the price was close to that level, after the second PIPE-307 failure but with the IPF trial well under way. One reading is that the market has written PIPE-307 down to little while keeping its valuation of the IPF option roughly unchanged.

Cash per share overstates downside protection, because the money is being spent on the trial by design.

SEC Form 10-Q: balance sheet and share count

13 Clinical risks and red flags

The risk list is short because the company is concentrated, and each item is material. The ranking below is an editorial judgment based on the filings reviewed.

• Single-asset dependence. With CTX-343 deferred and PIPE-307 in a partner’s hands after two misses, PIPE-791 in IPF carries almost all of the company’s value. A failed PROPEL-IPF would leave cash and a small discovery effort.
• Class safety. The first LPA1 antagonist from BMS was stopped for hepatobiliary toxicity, and on September 30, 2026 the trade press reported, with confirmation from a BMS spokesperson, added liver monitoring in the ALOFT program (BioPharma Dive). Any confirmed class effect would raise regulatory and enrollment hurdles for PIPE-791.
• Translation risk. PIPE-791’s lung target coverage is inferred from brain PET data and preclinical correlation; it has not been measured in human lungs.
• Effect size against background therapy. Patients may stay on nintedanib or pirfenidone, so PIPE-791 must show an incremental FVC benefit at 26 weeks in about 108 patients per arm.
• Enrollment and timing. Site counts are not enrollment counts. A delay beyond May 2028 would push the readout closer to the end of the runway.
• Partner opacity. J&J controls PIPE-307 and the license restricts Contineum’s disclosures; a decision may surface late or briefly.
• Dilution after success. A positive Phase 2 would require a far larger Phase 3; the ATM, the option pool and a likely financing make dilution a cost of success as much as of failure.
• Competitive pace. BMS is two Phase 3 programs ahead, and the IPF standard of care added Jascayd in 2025, raising the bar for a new mechanism.

Two common retail arguments deserve caution. Cash per share is not a floor while a trial consumes it, and the J&J milestone ceiling is not an asset: after September 14 its expected value is lower, and the balance sheet already carries it at zero.

Latest efficacy disclosure · SEC risk factors and liquidity · Class history slides

14 Retail sentiment on Stocktwits and social channels

Comments on social platforms come from non-professional traders and are not evidence about the drug.

On October 2, 2026 Stocktwits returned no sentiment score for $CTNM, a sign of low tagged activity. The message stream reviewed that day was thin and event-driven. On September 14 and 15 most posts simply relayed the MOONLIGHT-1 release and the company’s wording that J&J continues to evaluate the data. On September 29 several users asked what had caused the trading move before any news was visible to them; on September 30 posts circulated a summary of a sell-side note linking the move to the BMS protocol amendment. Merlintrader did not see the original note and does not reproduce its rating or target.

Retail attention reacts to partner and competitor news more than to Contineum’s rare releases; no post reviewed contained new primary information.

Stocktwits $CTNM stream

15 What to watch next and Merlintrader bottom line

Four signals will tell readers whether the reading on these pages still holds. First, the BMS ALOFT-IPF results, whenever BMS releases them: an efficacy effect consistent with Phase 2 and a manageable liver profile would support the class; anything else would weigh on PIPE-791 before its own data. Second, the Q3 2026 Form 10-Q, expected in the fourth quarter: liquid resources should fall roughly in line with the runway plan, and any change in the mid-2029 guidance would be important. Third, PROPEL-IPF operational disclosures and registry changes, especially the primary-completion estimate. Fourth, a formal J&J decision on PIPE-307.

Secondary signals: a chronic-pain decision, any ATM use and insider purchases (none filed in the period reviewed).

The bottom line: Contineum is a funded, concentrated development company whose story has been simplified by failure. PIPE-307 now looks like a free option controlled by a partner, not a pillar. PIPE-791 is a credible molecule in a validated but troubled drug class, tested in a properly sized, placebo-controlled trial that reads out in 2028. The cash buys that answer; it cannot replace it. Investors who follow the stock are, in practice, following Bristol Myers Squibb’s admilparant first and Contineum’s PIPE-791 second.

This is an editorial assessment of evidence and risk, with no author price target, no buy or sell instruction and no forecast of share performance.